SLC6A3 and depressive symptom measurement: An increase in ephedrines, BDNF, dopamine transporters, and serotonin results in increased expression of dopamine and serotonin receptors and decreased anxiety and depression (Heijnen et al., 2016 ▶; Shenas et al., 2021 ▶).